Loci# | Best model | Mean CV consistency | Mean prediction error % | p-value¶ | |
Gene(s) | SNP(s) | ||||
1–2 yrs | |||||
1 | CD86 | rs10804556 | 9.4 | 45.3 | 0.03 |
2 | CD86VTCN1 | rs10804556rs12030415 | 6.4 | 43.4 | 0.02 |
3 | VTCN1BTLACD274 | rs9288953rs7023227rs11805655 | 4.6 | 42.8 | 0.02 |
4 | VTCN1CD40CD86CTLA4 | rs9288953rs745307rs2332096rs231806 | 1.2 | 39.9 | 0.006 |
6–8 yrs | |||||
1 | ICOS | rs4521021 | 5.4 | 45.2 | 0.09 |
2 | CD274LILRA4 | rs4143815rs2241384 | 2.6 | 42.3 | 0.04 |
3 | TNFSF18LILRA4LILRB4 | rs975074rs2241385rs3745871 | 5.6 | 39.8 | 0.02 |
4 | CD276CD80CD80CD86 | rs11072430rs610902rs7648642rs4308217 | 1.4 | 38.1 | 0.006 |
SNP: single nucleotide polymorphism; CV: cross validation; CD: cluster of differentiation; VTCN1: V-set domain containing T-cell activation inhibitor 1; BTLA: B- and T-lymphocyte attenuator; CTLA4: cytotoxic T-lymphocyte-associated antigen 4; ICOS: inducible T-cell co-stimulator; LILRA4: leukocyte immunoglobulin-like receptor (LILR) subfamily A (with TM domain), member 4; TNFSF18: tumour necrosis factor (ligand) superfamily, member 18; LILRB4: LILR subfamily B (with TM and ITIM domains), member 4. #: number of loci considered; ¶: significance of prediction error (empirical p-value based on 1,000 permutations).